门冬氨酸鸟氨酸联合双歧杆菌三联活菌对亚临床肝性脑病的疗效观察

Clinical reserches of L-ornithin-L-aspartate and bifid triple viable tablet on the treatment of subclinical hepatic encephalopathy

[目的]观察门冬氨酸鸟氨酸联合双歧杆菌三联活菌治疗亚临床肝性脑病(SHE)的疗效。[方法]56例SHE患者按就诊科室随机分为2组,对照组(24例)予常规护肝治疗,治疗组(32例)在对照组治疗的基础上加门冬氨酸鸟氨酸及双歧杆菌三联活菌口服,2组均给药8周。测定2组治疗前后血氨水平、智力测验[数字连接试验(NCT)、数字符号试验(DST)]结果,并观察肝性脑病发病率。[结果]治疗组与对照组血氨水平、NCT、DST均有改善,治疗组治疗后血氨水平下降、DST缩短、SHE发病率下降,与对照组相比差异有统计学意义(P<0.05)。[结论]门冬氨酸鸟氨酸联合双歧杆菌三联活菌治疗可降低血氨水平,改善肠道菌群失调,降低肝性脑病的发病率。

Objective]To observe the clinical effects of L‐ornithin‐L‐aspartate and bifid triple viable tab‐let on the treatment of subclinical hepatic encephalopathy （SHE）.[Methods]Fifty‐six SHE patients were randomly divided into 2 groups.Patiens in the control group（24 cases）were given general supportive for 8 weeks.Patiens in the trial group（32 cases）were given L‐ornithin‐L‐aspartate and bifid triple viable tablet plus general supportive for 8 weeks too.[Results] Blood ammonia ,NCT and DST were improved in both group.There were significant difference in blood ammonia and DST between the two group.The SHE inci‐dence in the trial group was significantly lower than that in the control group.[Conclusion]L‐ornithin‐L‐as‐partate and bifid triple viable tablet can decrease blood ammonia and decrease the incidence of SHE.